Showing 5911-5920 of 21466 results for "".
- H9N2: Emerging Threat of a Potential Human Pandemichttps://reachmd.com/news/h9n2-emerging-threat-of-a-potential-human-pandemic/2484105/According to a Nature report, recent H9N2 avian influenza variants show genetic changes that increase binding to human-like receptors, raising
- Evaluating the Potential New Standard for HER2-Expressing Urothelial Carcinomahttps://reachmd.com/news/evaluating-the-potential-new-standard-for-her2-expressing-urothelial-carcinoma/2484109/In a pivotal Phase III trial presented at the 2025 ESMO
- CollPlant Launches US Logistics Hub to Support North American Growthhttps://reachmd.com/news/collplant-launches-us-logistics-hub-to-support-north-american-growth/2484120/CollPlant Biotechnologies has expanded its North American operations through a new partnership with a US-based logistics hub, the company announced. The center, expected to become operational this quarter, will support the growing distribution needs for CollPlant’s recombinant human collagen (rhC
- Bimekizumab Maintains Flare Control in HS Through 2 Yearshttps://reachmd.com/news/bimekizumab-maintains-flare-control-in-hs-through-2-years/2484119/Bimekizumab provides sustained control of disease flares in patients with moderate-to-severe hidradenitis suppurativa (HS), with more than 83% of patients remaining flare-free over 96 weeks, according to interim results from the BE HEARD EXT study presented by Dr. H
- Combination of Clascoterone 1% and Adapalene 0.3% Shows Promise for Acnehttps://reachmd.com/news/combination-of-clascoterone-1-and-adapalene-03-shows-promise-for-acne/2484118/Combination therapy with clascoterone cream 1% and adapalene gel 0.3% significantly improves acne severity and quality of life, while maintaining excellent tolerability in patients with moderate-to-severe acne vulgaris, according to a 16-week pilot study presented
- Nemolizumab Shows Durable Patient-Reported Benefits at 100 Weeks in PNhttps://reachmd.com/news/nemolizumab-shows-durable-patient-reported-benefits-at-100-weeks-in-pn/2484116/Long-term treatment with nemolizumab continues to deliver clinically meaningful improvements in itch, sleep, and quality of life for patients with prurigo nodularis (PN), according to interim results from the open-label extension (OLYMPIA-LTE) study presented by Dr
- New Review Highlights TWEAK/Fn14 Pathway's Potentialhttps://reachmd.com/news/new-review-highlights-tweakfn14-pathways-potential/2484097/A new review published in International Immunopharmacology explores the expanding role of the TWEAK/Fn14 signaling pathway in both skin disease pathogenesis and stem cell regulation, proposing its potential as a dual-purpose
- CHE Talk at Fall Clinical Highlights Precision Therapieshttps://reachmd.com/news/che-talk-at-fall-clinical-highlights-precision-therapies/2484094/With new FDA approvals, investigational therapies nearing the finish line, and a greater understanding of disease heterogeneity, chronic hand eczema (CHE) is increasingly viewed as a condition requiring individualized, mechanistically informed care, Alexandra Golant, MD, and Benjamin Ehst, MD, Ph
- Understanding Patient Priorities in Bladder Cancer Treatmenthttps://reachmd.com/news/understanding-patient-priorities-in-bladder-cancer-treatment/2484077/As treatment options for muscle-invasive bladder cancer (MIBC) continue to evolve—with immunotherapy and bladder-sparing protocols reshaping the landscape—a new study brings a crucial voice into the conversation: that of the patient.
- Emerging Biomarkers in Pediatric NAFLD: Beyond BMIhttps://reachmd.com/news/emerging-biomarkers-in-pediatric-nafld-beyond-bmi/2484084/In a prospective sample of 199 children, the triglyceride‑to‑HDL‑cholesterol ratio and the triglyceride‑glucose (TyG) index showed markedly higher sens